Compare Adaptive Biotechnologies Corp (ADPT) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs National Beverage Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while National Beverage Corp. trades at $32.97 (market cap $3.04B). The key difference: Adaptive Biotechnologies Corp and National Beverage Corp. are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| ADPT | FIZZ | |
|---|---|---|
Market Cap | $3.33B | $3.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $47.69 |
52-Week Low | $10.24 | $31.00 |
Enterprise Value | $3.19B | $2.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FIZZ (National Beverage Corp.) trades at $32.48, down 2.55% today, with a bearish technical signal and mixed earnings performance. The company maintains strong profitability with 15.56% net margin and 34.03% ROE, though revenue has stagnated around $1.2B annually. Recent news highlights a special $3.25 dividend announcement that boosted shares despite three consecutive quarterly earnings misses.
Outlook remains cautious with 50% of analysts rating Sell amid competitive pressures and consumer weakness. The dividend provides shareholder return but earnings consistency remains a concern. Key risks include tariff impacts and market saturation, while current valuation multiples appear reasonable given profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
